Core Viewpoint - The company has received approval for the listing application of the chemical raw material drug, Ferric Protein Succinylate, which marks a significant advancement in its raw material drug sector and supports its integrated development strategy in raw material and formulation [1][3]. Group 1: Drug Approval Details - The chemical raw material drug approved is Ferric Protein Succinylate, with a packaging specification of 10kg/bag and registration number Y20230001210 [1]. - The approval was granted by the National Medical Products Administration, confirming that the drug meets the relevant requirements for drug registration [1]. Group 2: R&D Investment - The company has invested approximately RMB 8.34 million (about 834.23 thousand) in the research and development of the Ferric Protein Succinylate project as of the announcement date [2]. Group 3: Market Position - As of the announcement date, there are 11 companies in China with an "A" registration status for Ferric Protein Succinylate, including the company and Jichuan Pharmaceutical Group [2]. Group 4: Strategic Impact - The approval of Ferric Protein Succinylate is expected to enhance the company's control over its raw material production and enrich its product structure, aligning with its strategic goals [3].

Group 1 - Company Jianhui Information plans to acquire 38% equity in Boke Guoxin for RMB 73.71 million, increasing its stake from 32% to 70%, making Boke Guoxin a subsidiary [1] - Company Guangshengtang's innovative drug GST-HG141 for hepatitis B has completed the enrollment of 578 participants in its Phase III clinical trial [2] - Company Hongjing Optoelectronics is establishing a partnership with a target scale of RMB 290 million, contributing RMB 3 million as a limited partner [3] Group 2 - Company Hongchang Technology intends to acquire 21% equity in Liangzhi Joint, which will make it the controlling shareholder with a 51% stake [4] - Company Xiexin Integrated has not yet received any orders in the "space photovoltaic" sector, which remains in the exploratory phase [5] - Company Xianheng International plans to reduce its shareholding by up to 3%, amounting to a maximum of 12.28 million shares [6] Group 3 - Company Furuijia plans to reduce its repurchased shares by up to 2%, totaling 18.93 million shares [7] - Company Tianqimo is planning to issue shares and pay cash to acquire assets, leading to a temporary suspension of its stock [8] - Company Shuangqiang Technology's director plans to reduce his holdings by up to 0.32% [9] Group 4 - Company Bairun plans to adjust the conversion price of its bonds due to stock prices falling below 85% of the conversion price [11] - Company Dongnan Network has won an EPC project worth RMB 994 million [12] - Company Anhui Energy has appointed Xu Wengong as the new general manager following the resignation of Fang Shiqing [13] Group 5 - Company Lijun plans to invest up to USD 3 million to establish subsidiaries in Hong Kong and Peru [14] - Company Zhenghe Ecology has signed a strategic cooperation agreement with the government of Beijing's Miyun District [15] - Company First Venture has elected Guo Chuan as the chairman of its board [16] Group 6 - Company Changxin Bochuang's shareholder has terminated an agreement to transfer 14.5 million shares [17] - Company Hengrui Medicine's HR091506 tablet application has been accepted by the National Medical Products Administration [18] - Company Hengrui Medicine's SHR-1894 injection has received approval for clinical trials [20] Group 7 - Company Longshen Rongfa has obtained a medical device production license [21] - Company Western Securities reported that its new borrowings exceeded 20% of its net assets [22] - Company Rongfa Nuclear Power's subsidiary has won a project worth RMB 101 million [23] Group 8 - Company Taiji Industry's subsidiary has a pre-bid for the Huahong FAB9B project with a bid amount of RMB 3.778 billion [24] - Company Suzhou High-tech plans to increase its investment in a subsidiary by RMB 780 million through a debt-to-equity swap [26] - Company Electric Power Investment's vice president has resigned due to work changes [27] Group 9 - Company Hengwei Technology reported a 30.13% increase in net profit for 2025 [28] - Company Fangsheng Pharmaceutical's subsidiary has received a drug production license [29] - Company Pilin Bio's subsidiary has received a notice for clinical trial acceptance for a hemostatic drug [31] Group 10 - Company Zhongxin Fluorine Material has received approval for a stock issuance to specific investors [32] - Company Shanhe Intelligent expects a total transaction amount with related parties to be RMB 1.197 billion in 2026 [33] - Company Warner Pharmaceutical's partner has completed Phase I clinical trials for a new drug [34]

Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. has received the approval notice for the listing application of the chemical raw material drug, Ferric Succinate, from the National Medical Products Administration, indicating compliance with national drug review technical standards [1] Group 1: Company Developments - The approval of Ferric Succinate marks a significant advancement in the company's layout in the raw material drug sector, enabling self-control over related raw materials [1] - This approval will further solidify the company's integrated development strategy of raw materials and formulations, contributing to a richer product structure [1]

Core Viewpoint - The approval of the chemical raw material drug application for Ferric Succinylate by the National Medical Products Administration marks a significant advancement for the company in the raw material drug sector, enhancing its strategic development and product structure [1] Group 1: Company Developments - The company’s subsidiary, Harbin Pharmaceutical Group Sanjing Ming Water Pharmaceutical Co., Ltd., received the approval notice for Ferric Succinylate [1] - This approval is a crucial step in the company's strategy to achieve self-control over its raw material drugs [1] - The approval will further solidify the company's integrated development strategy of raw materials and formulations, benefiting the diversification of its product structure [1]

Core Viewpoint - The approval of the chemical raw material drug application for Ferric Succinate by the National Medical Products Administration marks a significant advancement for the company in the raw material drug sector, enhancing its strategic development and product structure [1] Group 1: Regulatory Approval - The company’s subsidiary, Harbin Pharmaceutical Group Sanjing Ming Water Pharmaceutical Co., Ltd., received the approval notice for Ferric Succinate from the National Medical Products Administration [1] - The approval number for the application is 2026YS00100 [1] Group 2: Strategic Implications - The approval signifies an important step in the company's layout within the raw material drug field, allowing for greater autonomy and control over its raw material production [1] - This development will further solidify the company's integrated strategy of raw material and formulation development, benefiting the diversification of its product offerings [1]